Impact of Excipient Extraction and Buffer Exchange on Recombinant Monoclonal Antibody Stability
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.3c01157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Deepika Sarin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Indian Institute of Technology, Delhi, Hauz Khas, New Delhi 110016, India. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FDA HHS, U.S. Food and Drug Administration, Agilent Technologies.
Abstract (Originalsprache)
The foundation of a biosimilar manufacturer's regulatory filing is the demonstration of analytical and functional similarity between the biosimilar product and the pertinent originator product. The excipients in the formulation may interfere with characterization using typical analytical and functional techniques during this biosimilarity exercise. Consequently, the producers of biosimilar products resort to buffer exchange to isolate the biotherapeutic protein from the drug product formulation. However, the impact that this isolation has on the product stability is not completely known. This study aims to elucidate the extent to which mAb isolation via ultrafiltration-diafiltration-based buffer exchange impacts mAb stability. It has been demonstrated that repeated extraction cycles do result in significant changes in higher-order structure (red-shift of 5.0 nm in fluorescence maxima of buffer exchanged samples) of the mAb and also an increase in formation of basic variants from 19.1 to 26.7% and from 32.3 to 36.9% in extracted innovator and biosimilar Tmab samples, respectively. It was also observed that under certain conditions of tertiary structure disruptions, Tmab could be restabilized depending on formulation composition. Thus, mAb isolation through extraction with buffer exchange impacts the product stability. Based on the observations reported in this paper, we recommend that biosimilar manufacturers take into consideration these effects of excipients on protein stability when performing biosimilarity assessments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical Engineering, Indian Institute of Technology, Delhi, Hauz Khas, New Delhi 110016, India.
- School of Interdisciplinary Research, Indian Institute of Technology, Delhi, Hauz Khas, New Delhi 110016, India.
- Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, United States.
- Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, United States.
ORCID-Profile: M Reza Nejadnik, Raj Suryanarayanan, Anurag S Rathore
Förderung
- FDA HHS
- U.S. Food and Drug Administration
- Agilent Technologies
Zitieren
APA
Sarin, D., Krishna, K., Nejadnik, M. R., Suryanarayanan, R., & Rathore, A. S. (2024). Impact of Excipient Extraction and Buffer Exchange on Recombinant Monoclonal Antibody Stability. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c01157
Vancouver
Sarin D, Krishna K, Nejadnik MR, Suryanarayanan R, Rathore AS. Impact of Excipient Extraction and Buffer Exchange on Recombinant Monoclonal Antibody Stability. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c01157
BibTeX
@article{Sarin2024,
author = {Sarin, Deepika and Krishna, Kunal and Nejadnik, M Reza and Suryanarayanan, Raj and Rathore, Anurag S},
title = {Impact of Excipient Extraction and Buffer Exchange on Recombinant Monoclonal Antibody Stability},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.3c01157}
}
EUVIMED